| First Author | Zhu EF | Year | 2015 |
| Journal | Cancer Cell | Volume | 27 |
| Issue | 4 | Pages | 489-501 |
| PubMed ID | 25873172 | Mgi Jnum | J:220303 |
| Mgi Id | MGI:5634200 | Doi | 10.1016/j.ccell.2015.03.004 |
| Citation | Zhu EF, et al. (2015) Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2. Cancer Cell 27(4):489-501 |
| abstractText | Cancer immunotherapies under development have generally focused on either stimulating T cell immunity or driving antibody-directed effector functions of the innate immune system such as antibody-dependent cell-mediated cytotoxicity (ADCC). We find that a combination of an anti-tumor antigen antibody and an untargeted IL-2 fusion protein with delayed systemic clearance induces significant tumor control in aggressive isogenic tumor models via a concerted innate and adaptive response involving neutrophils, NK cells, macrophages, and CD8(+) T cells. This combination therapy induces an intratumoral "cytokine storm" and extensive lymphocyte infiltration. Adoptive transfer of anti-tumor T cells together with this combination therapy leads to robust cures of established tumors and development of immunological memory. |
